Acumen Pharmaceuticals (ABOS) Change in Cash (2020 - 2026)
Acumen Pharmaceuticals (ABOS) posted Change in Cash of -$2.2 million for Q1 2026, down 130.65% sequentially from $7.2 million in Q4 2025, and up 59.89% YoY from -$1.4 million in Q1 2025.
Acumen Pharmaceuticals (ABOS) Change in Cash (2020 - 2026) Analysis & Trends
Acumen Pharmaceuticals has reported Change in Cash for 7 years, with the latest figure at -$2.2 million in Q1 2026.
- Quarterly Change in Cash rose 59.89% year-over-year to -$2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.6 million (up 228.99% YoY) and the FY2025 annual result came in at $18.4 million, up 158.74% from the prior year.
- Change in Cash retreated to -$2.2 million in Q1 2026 per ABOS's latest filing, from $7.2 million in the prior quarter.
- Over five years, Change in Cash peaked at $46.5 million in Q3 2022 and troughed at -$52.1 million in Q1 2023.
- A 5-year average of -$4.1 million and a median of -$751000.0 in 2023 frame the typical range for Change in Cash.
- The sharpest annual moves came in 2022 and 2024: Change in Cash tumbled 465.32% in 2022, then soared 2899.73% in 2024.
- Over 5 years, Change in Cash stood at -$27.4 million in 2022, then fell by 2.0% to -$28.0 million in 2023, then soared by 108.71% to $2.4 million in 2024, then surged by 193.4% to $7.2 million in 2025, then plunged by 130.65% to -$2.2 million in 2026.
- According to Business Quant data, Change in Cash over the past three periods registered -$2.2 million, $7.2 million, and $10.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Acumen Pharmaceuticals | 226.87 Mn | 226.87 Mn | - | 7.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.65 Mn |
| Mar 31, 2026 | -2.19 Mn |
| Dec 31, 2025 | 7.16 Mn |
| Sep 30, 2025 | 10.02 Mn |
| Jun 30, 2025 | 6.65 Mn |
| Mar 31, 2025 | -5.47 Mn |
| Dec 31, 2024 | 2.44 Mn |
| Sep 30, 2024 | -34.77 Mn |
| Jun 30, 2024 | 21.03 Mn |
| Mar 31, 2024 | -19.96 Mn |
| Dec 31, 2023 | -27.99 Mn |
| Sep 30, 2023 | 17.86 Mn |
| Jun 30, 2023 | -751,000.00 |
| Mar 31, 2023 | -52.10 Mn |
| Dec 31, 2022 | -27.44 Mn |
| Sep 30, 2022 | 46.47 Mn |
| Jun 30, 2022 | 2.30 Mn |
| Mar 31, 2022 | -13.40 Mn |
| Dec 31, 2021 | -13.64 Mn |
| Sep 30, 2021 | 66.99 Mn |